Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) Research & Development (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Research & Development for 4 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 80.87% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.5 million, a 57.94% decrease, with the full-year FY2025 number at $19.5 million, down 57.94% from a year prior.
  • Research & Development was $4.1 million for Q4 2025 at Spruce Biosciences, down from $5.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $21.5 million in Q4 2024 to a low of -$430000.0 in Q2 2025.
  • A 4-year average of $9.4 million and a median of $8.9 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 93.31% in 2024, then crashed 105.32% in 2025.
  • Spruce Biosciences' Research & Development stood at $8.8 million in 2022, then increased by 25.58% to $11.1 million in 2023, then skyrocketed by 93.31% to $21.5 million in 2024, then plummeted by 80.87% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Research & Development are $4.1 million (Q4 2025), $5.0 million (Q3 2025), and -$430000.0 (Q2 2025).